Two cases of refractory polymyositis accompanied with steroid myopathy

Abstract Polymyositis (PM) is an inflammatory muscle disease characterized by chronic inflammation in skeletal muscle. Although most patients with PM respond to corticosteroids, some cases show an unsatisfactory response and other therapeutic options must be considered. Furthermore, glucocorticoster...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2015-01, Vol.25 (1), p.143-149
Main Authors: Izumi, Yasumori, Miyashita, Taiichiro, Kitajima, Tsubasa, Yoshimura, Shunsuke, Takeoka, Atsushi, Eguchi, Katsumi, Motomura, Masakatsu, Kawakami, Atsushi, Migita, Kiyoshi
Format: Article
Language:English
Subjects:
Amino acids
Female
Glucocorticoids - adverse effects
Glucocorticoids - therapeutic use
Humans
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Medical treatment
Middle Aged
Muscle Weakness - chemically induced
Muscle Weakness - drug therapy
Muscle, Skeletal - drug effects
Musculoskeletal system
Older people
Polymyositis - drug therapy
Tacrolimus - therapeutic use
Toxicity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Polymyositis (PM) is an inflammatory muscle disease characterized by chronic inflammation in skeletal muscle. Although most patients with PM respond to corticosteroids, some cases show an unsatisfactory response and other therapeutic options must be considered. Furthermore, glucocorticosteroid (GC) toxicity leads to a significant disability known as steroid myopathy, particularly in elderly patients. Here we report two patients with refractory PM. Combined treatment with high-dose GCs, tacrolimus, and intravenous immunoglobulin resulted in beneficial effects against myositis. However, muscle weakness and the disability progressed due to steroid myopathy, and subsequent oral intake became impossible because of swallowing disturbance in these two patients. Nutritional intervention, including branched-chain amino acids (BCAAs) and rehabilitation, was undertaken in addition to treatment against myositis. These treatments finally improved the muscle weakness and activities of daily living, and the two patients were discharged after recovery. The high-dose GC treatment caused elevation of serum levels of amino acids, including BCAAs, but these amino acids subsequently declined during BCAA replacement therapy. These findings suggest that the catabolic effects of the glucocorticoid treatment impair the balance of amino acids, including BCAAs, within the muscle, leading to steroid myopathy.
ISSN:1439-7595
1439-7609
DOI:10.3109/14397595.2013.874750